Target intelligence / Profile preview

CD4+ T cell proliferation signaling pathways (JNK, ERK, and PI3K-AKT regulated)

Molecular classification
Signaling pathway, Not a single molecular class; includes kinases and adaptor molecules of the PI3K-AKT, MAPK/ERK, and JNK families.
01

Overview

The process described encompasses the canonical intracellular signaling cascades regulating CD4+ T cell activation, survival, and proliferation. Engagement of the T cell receptor (TCR) and co-stimulatory molecules activates signaling pathways such as PI3K/AKT, ERK (a MAP kinase), and JNK (c-Jun N-terminal kinase), which orchestrate gene expression, metabolism, cell cycle progression, and cell survival. These pathways not only drive immune responses but are critical in maintaining the balance between tolerance and activation. Dysregulation is implicated in cancer, autoimmune disease, and immunodeficiency disorders. Each pathway includes multiple kinases and adaptors, not a single target.

Other names
T cell proliferation signaling pathwaysCD4+ T cell activation pathwaysPI3K/AKT, ERK, and JNK cascades in T cell proliferation
02

Mechanism of action

Inhibition or modulation of PI3K, AKT, ERK, or JNK kinases to alter T cell proliferation, survival, or immune function; mTOR inhibition (rapamycin impairs T cell proliferation by targeting a downstream effector)

03

Biological functions

Cell proliferationImmune responseCell survivalApoptosis regulationT cell differentiation
04

Disease associations

Cancer (through dysregulated proliferation or immune evasion)InflammationInfectionAutoimmune diseasesImmunodeficiency (via impaired T cell responses)
05

Safety considerations

Immunosuppression (risk of infection)Off-target effects (as these pathways are present in many cell types)Potential for impaired immune surveillance or tolerance (risk of autoimmunity or reduced anticancer immunity)
06

Interacting drugs

rapamycin (for mTOR)

3 more in the full profile.

07

Biomarkers

Phosphorylated AKT (p-AKT S473)Phosphorylated ERK, JNK (markers of pathway activation)Downstream cytokines (e.g., IL-2)

Beyond the preview

Go deeper on CD4+ T cell proliferation signaling pathways (JNK, ERK, and PI3K-AKT regulated).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD4+ T cell proliferation signaling pathways (JNK, ERK, and PI3K-AKT regulated).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call